Immunoassay Markets: Global Analysis and Opportunity Evaluation 2016 - 2020
This market report provides a comprehensive and easy-to-review analysis of the immunoassay market 2016 to 2020, providing key market data and identifying new and emerging opportunities across this field. This analysis is based on primary data disclosed by experienced end-users on their current immunoassay practices and their plans over the next three years. Its findings provide a wealth of market information on immunoassay and enable suppliers to target new markets and reduce costs.
Research Use of Immunoassay
More than 50 companies are mentioned in this report and these include Abbott Laboratories, Abcam, AccuBioTech, BD, Beckman Coulter, Berthold, Biohit, Biomerica, Biomerieux, Bio-Rad, Biotek, Biotron Diagnostics, BMG Labtech, Core Life Sciences, Diasorin, Dynex, Euroimmun, Fisher Scientific, GE Healthcare, Hema Diagnostic Systems, Idexx, Isogen Life Sciences Immunodiagnostics, Life Technologies, Luminex Corp, Molecular Devices, Molecular Diagnostics, Operon, Perkin Elmer, Pointe Scientific, Pro-Lab Diagnostics, Qiagen, Quanterix Corp, R-Biopharm AG, Roche Diagnostics, Samsung, Siemens, Tecan and Thermo Fisher and others.
This Report
Immunoassays are biochemical test that measures the presence or concentration of an analyte by the use of antibodies. This technique is widely used in clinical and life science laboratories, in research, screening and routine tests in diagnostics and therapeutic monitoring. Immunoassay is also seeing new advances and its use continues to grow as new applications are developed. This report presents the findings of a new global study of immunoassay that profiled the laboratory use of this technique across research, life science and clinical sectors.
Biopharm Reports' specialised market studies are designed to assist suppliers and developers to profile current and evolving laboratory market opportunities. All of our studies are carried out through specialist groups of experienced end-users and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:
Immunoassay Market Study
Growth
Based on recent trends in the numbers of samples analysed in their laboratories using immunoassay, end-user's own estimates of by how much (% increase or % decrease) their laboratory use of immunoassay has changed over the last three years. Also, based on current trends in the numbers of samples analysed in their laboratories, end-user's own estimates of by how much (% increase or % decrease) they anticipate their laboratory use of immunoassay will change over the next three years.
Immunoassay Instrument Suppliers ++
Clinical & Research Use: End-users' current main suppliers of immunoassay instruments (i.e. readers) and those companies they anticipate will be supplying immunoassay instruments (readers) to their laboratories in three years from now, where the companies++ considered were 1 Step Detect Associates, Abbott Laboratories, Abcam, Access Bio, AccuBioTech, Accutech, ACON Laboratories, Aesku Diagnostics, Akers Biosciences, Akrivis Technologies, Alere, Alfa Scientific Designs, ALPCO, Alverix (BD), Amedica Biotech, American Bio Medica Corp, AmniSure (Qiagen), Ani Biotech Oy, Anjue, Audit Diagnostics, Augurex Life Sciences Corp, Autobio Diagnostics, Awareness Tech, AXA Diagnostics, Axela, Axis-Shield plc (Alere), AXO Science, BD, Beckman Coulter, Berthold, BG Medicine, Bhat Bio-Tech India, Binding Site Group, Biohit (BioHIt Healthcare), Biokit (Werfen Group), Biomerica, Biomerieux, BioPorto Diagnostics, Bio-Rad Laboratories, Bioscience Diag Tech, Biosensia, BioSystems International, Biotek, Biotron Diagnostics, BMG Labtech, Boditech Med, Bioserv Diagnostics, BSMED, Calypte Biomedical Corp, CardioGenics, CD Diagnostics, CerTest Biotec, CHINCAN, Cisbio Bioassays, Clarity Diagnostics, Clearbridge BioLoc, Clinical Innovations, Concateno (Alere), Confirm Biosciences, Core Life Sciences, Corgenix Medical, Coris BioConcept, Critical Diagnostics, CTK Biotech, Inc., Cytonics Corp, D & J, Danaher Corp, Denka Seiken, Devon Medical, DFI Co, diaDexus, DIALAB, Diamedix Corp, Diametra, DianGong, Diasorin, DIAsource ImmunoAssays, DiaSys Diagnostic Systems, DIESSE Diagnostica Senese, Dr. Fooke Laboratorien, DRG International, D-tek, Dynex, EDP Biotech Corp, EKF Diagnostics, Elite Medical, Epocal, ERBA Diagnostics, Euroimmun, First Check Diagnostics Corp, Fisher Scientific, Focus Diagnostics, FujiFilm, Fujirebio, Fullmedi, GE Healthcare, GeneFluidics, Germaine Laboratories, Getein Biotech, GlysBy, Gold Standard Diagnostics, Grifols, GY, Hamamatzu, Heales, HealthLinx Limited, Hema Diagnostic Systems, HemoCue, Hemosure, Hidex, Hightop, Hologic, Hycor, Idexx, IDS, IMMCO Diagnostics (Trinity), Immunetics, Immunodiagnostics, Immuno-Mycologics, InBios International, INOVA Diagnostics, InTec Products, International Immuno-Diagnostics, INV 100, Isogen Life Sciences, Jant Pharmacal Corp, Jei Daniel Biotech Corp, JOY JUN, JYbiotech, Kronus, LabLogic, Labon, Labor Diagnostika Nord, Labsystems Diagnostics, Landcom, Leica Biosystems, Lepud Medical, Leyte, Life technologies, LifeSign, Liming Bio-Products, LOSUN, Luminex Corp, MagnaBioSciences, Maroche, MAYA, MBio Diagnostics, MECAN, Molecular Devices, Molecular Diagnostics, OEM Systems, Olympus Diagnostics, Omega Diagnostics, OncoHealth Corp, Operon, OPKU Health, OraSure Technologies, Orgentec Diagnostika, Ortho Clinical, Pan Probe Biotech, Perfemed Group, Perkin elmer, Perlong, Pointe Scientific, Polymed Therapeutics, Polymedco, Preventis, Princeton Biomeditech, Pro-Lab Diagnostics, Protagen, Qiagen, Qualigen, Quanterix Corp, Radiometer Medical, Randox, Rapid Pathogen Screening, R-Biopharm AG, Readwell, Reagena Group, Real World Diagnostics, Response Biomedical Corp, Reszon Diagnostics, Roche Diagnostics, SA Scientific, Samsung, Savyon Diagnostics, ScheBo-Biotech, Sekisui Diagnostics, Shanghai Upper Biotech, Shenzhen New Industries, Siemens, Siloam Biosciences, SNIBE, SQi Diagnostics, Standard Diagnostics (Alere), SunShineMed, Sysmex Corp, Tecan, Theradiag, Thermo Fisher, Tosoh Corp, Transasia Bio-Medicals, Trinity Biotech, True Diagnostics, Turklab Medical Devices, UCP Biosciences, Urit Medical, US Diagnostics, Utrao, VEDA, Vircell, Vital Diagnostics (ELITech), Wako Diagnostics, WAMA Diagnostica and any others.
++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party
Immunoassay Instruments (by Model Number)
Clinical & Research Use: End-users' current main immunoassay instruments (i.e. readers) and those immunoassay instruments (readers) they anticipate using in their laboratories in three years from now, where the instruments considered were Abbott Laboratories-ARCHITECT ci16200,Abbott Laboratories-ARCHITECT ci4100,Abbott Laboratories-ARCHITECT ci8200,Abbott Laboratories-ARCHITECT i1000SR,Abbott Laboratories-ARCHITECT i2000SR,Abbott Laboratories-ARCHITECT i4000SR,Abcam-Dipstick Reader,AccuBioTech-Elisa Reader (ABER-2),AESKU DIAGNOSTICS-HELIA,Alverix (BD)-BD Veritor,AmniSure (Qiagen)-Rapid Reader,Autobio Diagnostics-PHOmo,Awareness Tech-ChemWell® 2910,BD-BD Veritor,Beckman Coulter-Access 2,Beckman Coulter-UniCel DxC 660i,Beckman Coulter-UniCel® DxC 860i,Beckman Coulter-UniCel® DxI 600,Beckman Coulter-UniCel® DxI 800,Berthold-Apollo 11 LB 913,Berthold-Artemis K-101,Berthold-Centro LB 960,Berthold-CentroPRO LB 962,Berthold-Mithras LB 940,Berthold-TriStar2 LB 942,Biokit (Werfen Group)-BIO-FLASH,Biomerieux-Mini Vidas,Biomerieux-Vidas,Bio-Rad Laboratories-Elite,Bio-Rad Laboratories-PhD Ix System,Bio-Rad Laboratories-PR4100,Bioscience Diag Tech-Peteck96-1,Biosensia-RapiPlex,BioTek Instruments-Cytation 5,BioTek Instruments-ELx800,Biotek-Cytation 3,Biotek-Synergy 2,Biotek-Synergy H1,Biotek-Synergy H4,Biotek-Synergy NEO,BMG Labtech-CLARIOstar,BMG Labtech-FLUOstar,BMG Labtech-LUMIstar,BMG LABTECH-PHERAstar,BMG Labtech-POLARstar,BMG Labtech-SPECTROstar,BMG-NEPHELOstar Plus,BMG-PHERAstar Nano,Boditech Med Inc.-ichroma,CardioGenics Holdings-QL Care,Clearbridge BioLoc-AssayQuest,Core Life Sciences-PHOmo,Corgenix Medical-SkyLAB752,DIALAB-Autolyser 450,Diamedix Corp-Diamedix MAGO,Diasorin-ETI-MAX 3000,Diasorin-LAISON XL,DIAsource Immuno Assays-DIAspot Reader,DIAsource ImmunoAssays-Neptune,DiaSys Diagnostic Systems-StarDust MC15,DIESSE Diagnostica Senese-Seramat,DRG International-HYBRiD-XL,D-tek-BlueDiver,Dynex Technologies-Agility,Dynex Technologies-DSX,Dynex Technologies-Dynex DS2,Epocal-Epoc,ERBA Diagnostics-Dynex DS2,ERBA-Erba Lisa Scan EM,ERBA-Erba Lisa Scan II,ERBA-Mago 4,Euroimmun-IF Sprinter,Fisher Scientific-Diamedix MAGO,GeneFluidics-Proteus Robotic,Getein Biotech-GP FIA8000,Gold Standard Diagnostics Corp-ThunderBolt,Hidex-Sense,HYCOR Biomedical-HYTEC 288 Plus,IDS-IDS-iSYS,Immunodiagnostics-IDS-iSYS,Innova Diagnostics-BIO-FLASH,INOVA Diagnostics-Best 2000,INOVA Diagnostics-BIO-FLASH,INOVA Diagnostics-DSX,INOVA Diagnostics-Dynex DS2,INOVA Diagnostics-Quanta Lyser 2,INOVA Diagnostics-Quanta Lyser 240,International Immuno-Diagnostics-Manual EIA Reader,International Immuno-Diagnostics-Stat Fax 2100,International Immuno-Diagnostics-TKA 310,International Immuno-Diagnostics-TKA 500 Line,Isogen Life Sciences-LUMIstar Omega,Jei Daniel Biotech Corp.-Immuno Gold Reader,LabLogic-Hidex Sense,MBio Diagnostics-LightDeck,Molecular Devices-EMax Plus,Molecular Devices-FlexStation 3,Molecular devices-Spectramax i3,Molecular devices-Spectramax M5e,Molecular devices-Spectramax PARADIGM,Molecular Devices-VMax Kinetic,Molecular Diagnostics-VersaMax,OPKU Health-The Claros analyzer,Ortho Clinical-ORTHO VISION,Ortho Clinical-VITROS 3600,Ortho Clinical-VITROS Eci,Perfemed Group-Elisa Microplate,Pointe Scientific-Pointe 180 SR,Princeton Biomeditech-DXpress Reader,Qualigen-The FastPack IP System,Quanterix Corp-Simoa HD-1 analyzer,Radiometer Medical ApS-AQT90 FLEX,Randox-Evidence Evolution,Randox-Evidence Investigator,Roche Diagnostics-Cobas 411,Roche Diagnostics-cobas 6000,Roche Diagnostics-Cobas 601,Roche Diagnostics-Cobas 602,Roche Diagnostics-cobas 8000,Roche Diagnostics-cobas e411,Siemens Healthcare:-ADVIA Centaur CP,Siemens Healthcare:-ADVIA Centaur XP,Siemens Healthcare:-ADVIA Centaur XPT,Siemens Healthcare:-Dimension EXL 200,Siemens Healthcare:-Dimension Vista 1500,Siemens Healthcare:-Dimension Vista 500,Siemens Healthcare:-Immulite 2000 Xpi,Siemens-Dimension Xpand Plus,Siemens-Dimention EXL,Siemens-Dimention RxL Max,Siemens-Dimention Vista 1500,Siemens-Dimention Vista 3000T,Siemens-Immulite 1000,Siemens-Immulite 2000,SQi Diagnostics-Sqidlite,SQi Diagnostics-Sqidworks,SQi Diagnostics-Sqid-X,Tecan-Infinite 200 PRO NanoQuant,Tecan-Infinite F200 PRO,Tecan-Infinite F50,Tecan-Infinite F500,Tecan-Infinite M1000 PRO,Tecan-Infinite M200,Tecan-Spark 10M,Tecan-Sunrise,Theradiag-CARIS,Theradiag-Chorus,Theradiag-FIDIS, Theradiag-Theralis µ,Theradiag-Theralis,Thermo Fisher-Fluoroskan Ascent,Thermo Fisher-Luminoskan Ascent,Thermo Fisher-Multiskan,Thermo Fisher-Phadia System 100,Thermo Fisher-Phadia System 1000,Thermo Fisher-Phadia System 250,Thermo Fisher-Phadia System 2500, Thermo Fisher-Phadia System 5000,Thermo Fisher-Varioskan Flash,Thermo Fisher-Varioskan LUX,Tosoh Corp-AIA-1800,Tosoh Corp-AIA-2000,Tosoh Corp-AIA-360,Tosoh Corp-AIA-600 II,Tosoh Corp-AIA-900,Transasia Bio-Medicals-Elan 30 s,Transasia Bio-Medicals-Erba Lisa Scan EM,Transasia Bio-Medicals-Erba Lisa Scan II,Transasia Bio-Medicals-Mago 4,VEDA.LAB-EASY READER 36100,Vircell S.L.-Dynex DS2 or any others.
Immunoassay Consumables Suppliers ++
Clinical & Research Use: End-users' current main suppliers of immunoassay consumables and those companies they anticipate will be supplying immunoassay consumables to their laboratories in three years from now, where the companies++ considered were 1 Step Detect Associates, Abbott Laboratories, Abcam, Access Bio, AccuBioTech, Accutech, ACON Laboratories, Aesku Diagnostics, Akers Biosciences, Akrivis Technologies, Alere, Alfa Scientific Designs, ALPCO, Alverix (BD), Amedica Biotech, American Bio Medica Corp, AmniSure (Qiagen), Ani Biotech Oy, Anjue, Audit Diagnostics, Augurex Life Sciences Corp, Autobio Diagnostics, Awareness Tech, AXA Diagnostics, Axela, Axis-Shield plc (Alere), AXO Science, BD, Beckman Coulter, Berthold, BG Medicine, Bhat Bio-Tech India, Binding Site Group, Biohit (BioHIt Healthcare), Biokit (Werfen Group), Biomerica, Biomerieux, BioPorto Diagnostics, Bio-Rad Laboratories, Bioscience Diag Tech, Biosensia, BioSystems International, Biotek, Biotron Diagnostics, BMG Labtech, Boditech Med, Bioserv Diagnostics, BSMED, Calypte Biomedical Corp, CardioGenics, CD Diagnostics, CerTest Biotec, CHINCAN, Cisbio Bioassays, Clarity Diagnostics, Clearbridge BioLoc, Clinical Innovations, Concateno (Alere), Confirm Biosciences, Core Life Sciences, Corgenix Medical, Coris BioConcept, Critical Diagnostics, CTK Biotech, Inc., Cytonics Corp, D & J, Danaher Corp, Denka Seiken, Devon Medical, DFI Co, diaDexus, DIALAB, Diamedix Corp, Diametra, DianGong, Diasorin, DIAsource ImmunoAssays, DiaSys Diagnostic Systems, DIESSE Diagnostica Senese, Dr. Fooke Laboratorien, DRG International, D-tek, Dynex, EDP Biotech Corp, EKF Diagnostics, Elite Medical, Epocal, ERBA Diagnostics, Euroimmun, First Check Diagnostics Corp, Fisher Scientific, Focus Diagnostics, FujiFilm, Fujirebio, Fullmedi, GE Healthcare, GeneFluidics, Germaine Laboratories, Getein Biotech, GlysBy, Gold Standard Diagnostics, Grifols, GY, Hamamatzu, Heales, HealthLinx Limited, Hema Diagnostic Systems, HemoCue, Hemosure, Hidex, Hightop, Hologic, Hycor, Idexx, IDS, IMMCO Diagnostics (Trinity), Immunetics, Immunodiagnostics, Immuno-Mycologics, InBios International, INOVA Diagnostics, InTec Products, International Immuno-Diagnostics, INV 100, Isogen Life Sciences, Jant Pharmacal Corp, Jei Daniel Biotech Corp, JOY JUN, JYbiotech, Kronus, LabLogic, Labon, Labor Diagnostika Nord, Labsystems Diagnostics, Landcom, Leica Biosystems, Lepud Medical, Leyte, Life technologies, LifeSign, Liming Bio-Products, LOSUN, Luminex Corp, MagnaBioSciences, Maroche, MAYA, MBio Diagnostics, MECAN, Molecular Devices, Molecular Diagnostics, OEM Systems, Olympus Diagnostics, Omega Diagnostics, OncoHealth Corp, Operon, OPKU Health, OraSure Technologies, Orgentec Diagnostika, Ortho Clinical, Pan Probe Biotech, Perfemed Group, Perkin elmer, Perlong, Pointe Scientific, Polymed Therapeutics, Polymedco, Preventis, Princeton Biomeditech, Pro-Lab Diagnostics, Protagen, Qiagen, Qualigen, Quanterix Corp, Radiometer Medical, Randox, Rapid Pathogen Screening, R-Biopharm AG, Readwell, Reagena Group, Real World Diagnostics, Response Biomedical Corp, Reszon Diagnostics, Roche Diagnostics, SA Scientific, Samsung, Savyon Diagnostics, ScheBo-Biotech, Sekisui Diagnostics, Shanghai Upper Biotech, Shenzhen New Industries, Siemens, Siloam Biosciences, SNIBE, SQi Diagnostics, Standard Diagnostics (Alere), SunShineMed, Sysmex Corp, Tecan, Theradiag, Thermo Fisher, Tosoh Corp, Transasia Bio-Medicals, Trinity Biotech, True Diagnostics, Turklab Medical Devices, UCP Biosciences, Urit Medical, US Diagnostics, Utrao, VEDA, Vircell, Vital Diagnostics (ELITech), Wako Diagnostics, WAMA Diagnostica and any others.
++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party
Market Size (Study Group)
As part of this study, end-users provided details of their immunoassy per-sample costs, together with the numbers of immunoassay runs they carry out on a monthly basis. These data allow an estimate of the annual market size corresponding to the running costs of immunoassay, associated with this group of 228 end-users. This is based on an average value of the per-sample costs and an average value for the number of sample runs per month. Purchasers of the Global License for this report are able to analyse these financial figures across all market sectors covered in this study. Also, these financial figures allow companies to estimate immunoassy 'running cost' market sizes on a global, regional or country-wide basis, from their own independent figures of the associated numbers of immunoassay users.
Immunoassay Applications
Clinical & Research Use: End-users' current main immunoassay applications used in their laboratories and those immunoassy applications they anticipate they will be using in their laboratories in three years from now, where the applications considered were Alcohol screening, Allergy, Anemia, Antiphospholipid Syndrome (APS), Autoimmune, Blood Borne, Blood Genotyping, Bone, Brain damages, Breast Care, Cancer markers, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Circulating Immuno Complexes, Coagulation, Complement, Connective Tissue, Critical Care, Diabetes, Drug Abuse Tests, Endocrinology, Fertility, FOB Tests, Food Intolerance, Gastrointestinal, Genetic, Growth Factors, Hepatitis, Hormones, Hypertension, Immunology Markers, Infections – Bacterial, Infections – Viral, Inflammation, Liver Disease, Metabolism, Misfolded Proteins, Neurodegenerative diseases, Neuroscience, Newborn screening, Obesity, Ovulation, Perinatal, Pregnancy, Primary Immunodeficiency (PID), Rheumatoid Arthritis, Saliva Drug Screens, Sepsis, Sexually Transmitted, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Urine Tests, Vascular disease, Vasculitis, Veterinary, Vitamin deficiencies, Women's Health and any others.
Multimplexing of Immunoassay
Clinical & Research Use: End-users' current levels of multiplexing of immunoassay and the levels of multiplexing of immunoassy they anticipate they will be using in their laboratories in three years from now, where the multiplexing levels considerted were 1 to 5, 6 to 10, 15/11/2015 00:00:00, 16-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-150, 151 – 200, > 200 and No Multiplex Assays.
Immunoassay Types
Clinical & Research Use: End-users' current main immunoassay types used in their laboratories and those immunoassy types they anticipate they will be using in their laboratories in three years from now, where the immunoassay types considered were ELISA – Enzyme Linked ImmunoSorbent Assay, RIA – Radio-ImmunoAssay, EMIT – Enzyme Multiplied Immunoassay, FRET – Fluorescent Resonance Energy Transfer, FPIA – Fluorescent Polarized Immunoassay, KIMS – Kinetic Interaction of Microparticles in Solution, CEDIA – Cloned Enzyme Donor Immunoassay, Lateral Flow Immunoassay and any others.
Immunoassay Formats
Clinical & Research Use: End-users' current main immunoassay formats used in their laboratories and those immunoassy formats they anticipate they will be using in their laboratories in three years from now, where the immunoassay formats considered were Competitive, homogeneous immunoassay; Competitive, heterogeneous immunoassay; One-site, noncompetitive immunoassay and Two-site, noncompetitive immunoassay and any others.
Immunoassay Labels
Clinical & Research Use: End-users' current main immunoassay labels used in their laboratories and those immunoassy labels they anticipate they will be using in their laboratories in three years from now, where the immunoassay labels considered were Enzymes, Radioactive isotopes, DNA reporters, Fluorogenic reporters, Electrochemiluminescent tags, Labeless immunoassays and any others.
Innovation and Development Needs
Clinical & Research: Based on their own experience, end-users' views on the areas of greatest need for innovation or development in immunoassay, where the areas considered were Accuracy, Ambiguities, Applicability to 'difficult' samples, Consistancy, Convenience, Cost, Data interpretation, Ease of use, Extraction times, Multiplex capabilities, Immunoassay run times, Reagent degradation, Reliability, Robustness, Safety, Sensitivity, Service support, Size footprint, Software capabilities, Speed, Stability, Throughput, Versatility and any other areas.
Assay Costs
End user's estimates of the average costs of their immunoassay analyses for a typical study sample in their laboratory, where the cost levels considered were <$5, $5 - $10, $10 - $20, $20 - $30, $30 - $40, $40 - $50, $50 - $70, $70 - $100, $100 - $150, $150 - $250, $250 - $400, $400 - $600, $600 - $1000 and > $1000.
Sample Throughput
End user's estimates of the average number of study samples they analyse each month using immunoassay in their laboratory, where the throughput levels considered were <10, 10 - 20, 20 – 30, 30 – 40, 40 – 50, 50 – 70, 70 – 100, 100 – 150, 150 – 250, 250- 400, 400 – 600, 600 – 1000, 1000 – 1500, 1500 – 2000, 2000 – 2500 and > 2500.
Relative Assay Cost Areas
Clinical & Research: In terms of relative costs, end-users own estimates (on a scale of 1 - 7) of the different relative cost levels associated with their immunoassay consumables, where 1 is the lowest relative cost and 7 in the highest and where the options evaluated were Immunoassay kits and reagents, External services costs, Instrument service (maintenance) contracts, Plasticware (tips, tubes etc), Sample preparation (extraction) kits and reagents, Software licenses and any other.
Immunoassay Fields
End-users' current main fields of use of immunoassay, where the fields considered were Biochemistry, Biology, Biotechnology, Clinical Therapeutics, Clinical Diagnostics, Environmental, Food & Drink, Forensics, Government, Healthcare, Medicine, Natural Products, Pharmaceuticals, Veterinary and any other.
Broad Applications of Immunoassay
End-users current main broad applications of their immunoassay and those main broad applications they anticipate in three years from now, where the broad applications considered were Clinical Therapeutics – Treatment Decisions; Clinical Therapeutics – Treatment Monitoring; Clinical Therapeutics – Clinical Trials; Clinical Therapeutics – Research; Diagnostics – Routine patient Tests; Diagnostics – Patient Screening; Diagnostics – Research; Diagnostics – Disease Biomarkers; Drug R&D – Discovery; Drug R&D – Drug Targets; Drug R&D – Preclinical studies; Drug R&D – ADME; Drug R&D – Toxicology; Drug R&D – Drug Metabolism; Drug R&D – Clinical Trials; Bioprocesses; Bacteriology; Cytology; Cytogenetics; Genomics; Metabolomics; Proteomics; Virology and any other.
Immunoassay Environment
End-user's main environment for the use of immunoassay, where the environments considered were Laboratory, Point of Care (POC), Blood Screening or any other.
Disease Biomarkers
The disease areas to which their immunoassay is used, where the diseases considered were Arthritis, Autoimmune Diseases, Bone Metabolism, Cancer, Cardiovascular, Central Nervous System, Dentistry, Dermatology, Endocrine, Gastrointestinal, Genito-urinary System, Haematology, Infections, Inflammation, Metabolic Disorders, Musculoskeletal Disorders, Nutrition, Obstetrics and Gynaecology, Ophthalmology, Pain, Psychiatry, Respiratory, Skin, any other or None.
The purpose of their immunoassay disease biomarker studies, where the purposes considered were Biomarker Discovery, Clinical – Research, Clinical – Trials, Diagnostics – Screening, Diagnostics – Research, Diagnostics – Routine tests, Disease research, Drug R&D – Clinical trials, Drug R&D – Drug targets, Drug R&D – Preclinical, Drug R&D – ADME, Toxicology, Treatment – Decisions, Treatment – Monitoring or any other.
The clinical utility of their immunoassay disease biomarker studies, where the options considered were Companion diagnostics, Disease prognosis, Disease stage or severity, Disease susceptibility or risk, Disease variability, Drug discovery, Drug therapy dose, Early detection of disease, Guiding treatment, Multiple utilities, Response to therapy, Safety or toxicity factors, Screening and monitoring, Therapy decision-making or other.
Participants
Research Use of Immunoassay
- Growth in end-user's immunoassay analysis now and anticipated in 3 years (±% change)
- High-growth areas of immunoassay now and anticipated in 3 years (±% change)
- Immunoassay reader suppliers now and anticipated in 3 years (±% change)
- Immunoassay readers used now and anticipated in 3 years (±% change)
- Immunoassay consumables suppliers now and anticipated in 3 years (±% change)
- Three-year plans for the use of immunoassay
- Relative consumables costs relating to the use of immunoassay
- Immunoassay formats used now and anticipated in 3 years (±% change)
- Applications of immunoassay now and anticipated in 3 years (±% change)
- Immunoassay labels used now and anticipated in 3 years (±% change)
- Immunoassay types used now and anticipated in 3 years (±% change)
- Multiplexed immunoassay used now and anticipated in 3 years (±% change)
- Innovation and development needs relating to the future use of immunoassay
- Disease Biomarkers types, diseases, purposes, clinical utilities
- Sample types analysed analysed now and anticipated in 3 years (±% change)
- Diseases studied now and anticipated in 3 years (±% change)
- Growth in end-user's immunoassay analysis now and anticipated in 3 years (±% change)
- High-growth areas of immunoassay now and anticipated in 3 years (±% change)
- Immunoassay reader suppliers now and anticipated in 3 years (±% change)
- Immunoassay readers used now and anticipated in 3 years (±% change)
- Immunoassay consumables suppliers now and anticipated in 3 years (±% change)
- Three-year plans for the use of immunoassay
- Relative consumables costs relating to the use of immunoassay
- Immunoassay formats used now and anticipated in 3 years (±% change)
- Applications of immunoassay now and anticipated in 3 years (±% change)
- Immunoassay labels used now and anticipated in 3 years (±% change)
- Immunoassay types used now and anticipated in 3 years (±% change)
- Multiplexed immunoassay used now and anticipated in 3 years (±% change)
- Innovation and development needs relating to the future use of immunoassay
- Disease Biomarkers types, diseases, purposes, clinical utilities
- Sample types analysed analysed now and anticipated in 3 years (±% change)
- Diseases studied now and anticipated in 3 years (±% change)
- Costs of sample analysis estimated by end users, using immunoassay
- Average monthly throughput of samples by end users, using immunoassay
- Countries and global regions
- Organisation types
More than 50 companies are mentioned in this report and these include Abbott Laboratories, Abcam, AccuBioTech, BD, Beckman Coulter, Berthold, Biohit, Biomerica, Biomerieux, Bio-Rad, Biotek, Biotron Diagnostics, BMG Labtech, Core Life Sciences, Diasorin, Dynex, Euroimmun, Fisher Scientific, GE Healthcare, Hema Diagnostic Systems, Idexx, Isogen Life Sciences Immunodiagnostics, Life Technologies, Luminex Corp, Molecular Devices, Molecular Diagnostics, Operon, Perkin Elmer, Pointe Scientific, Pro-Lab Diagnostics, Qiagen, Quanterix Corp, R-Biopharm AG, Roche Diagnostics, Samsung, Siemens, Tecan and Thermo Fisher and others.
This Report
Immunoassays are biochemical test that measures the presence or concentration of an analyte by the use of antibodies. This technique is widely used in clinical and life science laboratories, in research, screening and routine tests in diagnostics and therapeutic monitoring. Immunoassay is also seeing new advances and its use continues to grow as new applications are developed. This report presents the findings of a new global study of immunoassay that profiled the laboratory use of this technique across research, life science and clinical sectors.
Biopharm Reports' specialised market studies are designed to assist suppliers and developers to profile current and evolving laboratory market opportunities. All of our studies are carried out through specialist groups of experienced end-users and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:
Immunoassay Market Study
Growth
Based on recent trends in the numbers of samples analysed in their laboratories using immunoassay, end-user's own estimates of by how much (% increase or % decrease) their laboratory use of immunoassay has changed over the last three years. Also, based on current trends in the numbers of samples analysed in their laboratories, end-user's own estimates of by how much (% increase or % decrease) they anticipate their laboratory use of immunoassay will change over the next three years.
Immunoassay Instrument Suppliers ++
Clinical & Research Use: End-users' current main suppliers of immunoassay instruments (i.e. readers) and those companies they anticipate will be supplying immunoassay instruments (readers) to their laboratories in three years from now, where the companies++ considered were 1 Step Detect Associates, Abbott Laboratories, Abcam, Access Bio, AccuBioTech, Accutech, ACON Laboratories, Aesku Diagnostics, Akers Biosciences, Akrivis Technologies, Alere, Alfa Scientific Designs, ALPCO, Alverix (BD), Amedica Biotech, American Bio Medica Corp, AmniSure (Qiagen), Ani Biotech Oy, Anjue, Audit Diagnostics, Augurex Life Sciences Corp, Autobio Diagnostics, Awareness Tech, AXA Diagnostics, Axela, Axis-Shield plc (Alere), AXO Science, BD, Beckman Coulter, Berthold, BG Medicine, Bhat Bio-Tech India, Binding Site Group, Biohit (BioHIt Healthcare), Biokit (Werfen Group), Biomerica, Biomerieux, BioPorto Diagnostics, Bio-Rad Laboratories, Bioscience Diag Tech, Biosensia, BioSystems International, Biotek, Biotron Diagnostics, BMG Labtech, Boditech Med, Bioserv Diagnostics, BSMED, Calypte Biomedical Corp, CardioGenics, CD Diagnostics, CerTest Biotec, CHINCAN, Cisbio Bioassays, Clarity Diagnostics, Clearbridge BioLoc, Clinical Innovations, Concateno (Alere), Confirm Biosciences, Core Life Sciences, Corgenix Medical, Coris BioConcept, Critical Diagnostics, CTK Biotech, Inc., Cytonics Corp, D & J, Danaher Corp, Denka Seiken, Devon Medical, DFI Co, diaDexus, DIALAB, Diamedix Corp, Diametra, DianGong, Diasorin, DIAsource ImmunoAssays, DiaSys Diagnostic Systems, DIESSE Diagnostica Senese, Dr. Fooke Laboratorien, DRG International, D-tek, Dynex, EDP Biotech Corp, EKF Diagnostics, Elite Medical, Epocal, ERBA Diagnostics, Euroimmun, First Check Diagnostics Corp, Fisher Scientific, Focus Diagnostics, FujiFilm, Fujirebio, Fullmedi, GE Healthcare, GeneFluidics, Germaine Laboratories, Getein Biotech, GlysBy, Gold Standard Diagnostics, Grifols, GY, Hamamatzu, Heales, HealthLinx Limited, Hema Diagnostic Systems, HemoCue, Hemosure, Hidex, Hightop, Hologic, Hycor, Idexx, IDS, IMMCO Diagnostics (Trinity), Immunetics, Immunodiagnostics, Immuno-Mycologics, InBios International, INOVA Diagnostics, InTec Products, International Immuno-Diagnostics, INV 100, Isogen Life Sciences, Jant Pharmacal Corp, Jei Daniel Biotech Corp, JOY JUN, JYbiotech, Kronus, LabLogic, Labon, Labor Diagnostika Nord, Labsystems Diagnostics, Landcom, Leica Biosystems, Lepud Medical, Leyte, Life technologies, LifeSign, Liming Bio-Products, LOSUN, Luminex Corp, MagnaBioSciences, Maroche, MAYA, MBio Diagnostics, MECAN, Molecular Devices, Molecular Diagnostics, OEM Systems, Olympus Diagnostics, Omega Diagnostics, OncoHealth Corp, Operon, OPKU Health, OraSure Technologies, Orgentec Diagnostika, Ortho Clinical, Pan Probe Biotech, Perfemed Group, Perkin elmer, Perlong, Pointe Scientific, Polymed Therapeutics, Polymedco, Preventis, Princeton Biomeditech, Pro-Lab Diagnostics, Protagen, Qiagen, Qualigen, Quanterix Corp, Radiometer Medical, Randox, Rapid Pathogen Screening, R-Biopharm AG, Readwell, Reagena Group, Real World Diagnostics, Response Biomedical Corp, Reszon Diagnostics, Roche Diagnostics, SA Scientific, Samsung, Savyon Diagnostics, ScheBo-Biotech, Sekisui Diagnostics, Shanghai Upper Biotech, Shenzhen New Industries, Siemens, Siloam Biosciences, SNIBE, SQi Diagnostics, Standard Diagnostics (Alere), SunShineMed, Sysmex Corp, Tecan, Theradiag, Thermo Fisher, Tosoh Corp, Transasia Bio-Medicals, Trinity Biotech, True Diagnostics, Turklab Medical Devices, UCP Biosciences, Urit Medical, US Diagnostics, Utrao, VEDA, Vircell, Vital Diagnostics (ELITech), Wako Diagnostics, WAMA Diagnostica and any others.
++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party
Immunoassay Instruments (by Model Number)
Clinical & Research Use: End-users' current main immunoassay instruments (i.e. readers) and those immunoassay instruments (readers) they anticipate using in their laboratories in three years from now, where the instruments considered were Abbott Laboratories-ARCHITECT ci16200,Abbott Laboratories-ARCHITECT ci4100,Abbott Laboratories-ARCHITECT ci8200,Abbott Laboratories-ARCHITECT i1000SR,Abbott Laboratories-ARCHITECT i2000SR,Abbott Laboratories-ARCHITECT i4000SR,Abcam-Dipstick Reader,AccuBioTech-Elisa Reader (ABER-2),AESKU DIAGNOSTICS-HELIA,Alverix (BD)-BD Veritor,AmniSure (Qiagen)-Rapid Reader,Autobio Diagnostics-PHOmo,Awareness Tech-ChemWell® 2910,BD-BD Veritor,Beckman Coulter-Access 2,Beckman Coulter-UniCel DxC 660i,Beckman Coulter-UniCel® DxC 860i,Beckman Coulter-UniCel® DxI 600,Beckman Coulter-UniCel® DxI 800,Berthold-Apollo 11 LB 913,Berthold-Artemis K-101,Berthold-Centro LB 960,Berthold-CentroPRO LB 962,Berthold-Mithras LB 940,Berthold-TriStar2 LB 942,Biokit (Werfen Group)-BIO-FLASH,Biomerieux-Mini Vidas,Biomerieux-Vidas,Bio-Rad Laboratories-Elite,Bio-Rad Laboratories-PhD Ix System,Bio-Rad Laboratories-PR4100,Bioscience Diag Tech-Peteck96-1,Biosensia-RapiPlex,BioTek Instruments-Cytation 5,BioTek Instruments-ELx800,Biotek-Cytation 3,Biotek-Synergy 2,Biotek-Synergy H1,Biotek-Synergy H4,Biotek-Synergy NEO,BMG Labtech-CLARIOstar,BMG Labtech-FLUOstar,BMG Labtech-LUMIstar,BMG LABTECH-PHERAstar,BMG Labtech-POLARstar,BMG Labtech-SPECTROstar,BMG-NEPHELOstar Plus,BMG-PHERAstar Nano,Boditech Med Inc.-ichroma,CardioGenics Holdings-QL Care,Clearbridge BioLoc-AssayQuest,Core Life Sciences-PHOmo,Corgenix Medical-SkyLAB752,DIALAB-Autolyser 450,Diamedix Corp-Diamedix MAGO,Diasorin-ETI-MAX 3000,Diasorin-LAISON XL,DIAsource Immuno Assays-DIAspot Reader,DIAsource ImmunoAssays-Neptune,DiaSys Diagnostic Systems-StarDust MC15,DIESSE Diagnostica Senese-Seramat,DRG International-HYBRiD-XL,D-tek-BlueDiver,Dynex Technologies-Agility,Dynex Technologies-DSX,Dynex Technologies-Dynex DS2,Epocal-Epoc,ERBA Diagnostics-Dynex DS2,ERBA-Erba Lisa Scan EM,ERBA-Erba Lisa Scan II,ERBA-Mago 4,Euroimmun-IF Sprinter,Fisher Scientific-Diamedix MAGO,GeneFluidics-Proteus Robotic,Getein Biotech-GP FIA8000,Gold Standard Diagnostics Corp-ThunderBolt,Hidex-Sense,HYCOR Biomedical-HYTEC 288 Plus,IDS-IDS-iSYS,Immunodiagnostics-IDS-iSYS,Innova Diagnostics-BIO-FLASH,INOVA Diagnostics-Best 2000,INOVA Diagnostics-BIO-FLASH,INOVA Diagnostics-DSX,INOVA Diagnostics-Dynex DS2,INOVA Diagnostics-Quanta Lyser 2,INOVA Diagnostics-Quanta Lyser 240,International Immuno-Diagnostics-Manual EIA Reader,International Immuno-Diagnostics-Stat Fax 2100,International Immuno-Diagnostics-TKA 310,International Immuno-Diagnostics-TKA 500 Line,Isogen Life Sciences-LUMIstar Omega,Jei Daniel Biotech Corp.-Immuno Gold Reader,LabLogic-Hidex Sense,MBio Diagnostics-LightDeck,Molecular Devices-EMax Plus,Molecular Devices-FlexStation 3,Molecular devices-Spectramax i3,Molecular devices-Spectramax M5e,Molecular devices-Spectramax PARADIGM,Molecular Devices-VMax Kinetic,Molecular Diagnostics-VersaMax,OPKU Health-The Claros analyzer,Ortho Clinical-ORTHO VISION,Ortho Clinical-VITROS 3600,Ortho Clinical-VITROS Eci,Perfemed Group-Elisa Microplate,Pointe Scientific-Pointe 180 SR,Princeton Biomeditech-DXpress Reader,Qualigen-The FastPack IP System,Quanterix Corp-Simoa HD-1 analyzer,Radiometer Medical ApS-AQT90 FLEX,Randox-Evidence Evolution,Randox-Evidence Investigator,Roche Diagnostics-Cobas 411,Roche Diagnostics-cobas 6000,Roche Diagnostics-Cobas 601,Roche Diagnostics-Cobas 602,Roche Diagnostics-cobas 8000,Roche Diagnostics-cobas e411,Siemens Healthcare:-ADVIA Centaur CP,Siemens Healthcare:-ADVIA Centaur XP,Siemens Healthcare:-ADVIA Centaur XPT,Siemens Healthcare:-Dimension EXL 200,Siemens Healthcare:-Dimension Vista 1500,Siemens Healthcare:-Dimension Vista 500,Siemens Healthcare:-Immulite 2000 Xpi,Siemens-Dimension Xpand Plus,Siemens-Dimention EXL,Siemens-Dimention RxL Max,Siemens-Dimention Vista 1500,Siemens-Dimention Vista 3000T,Siemens-Immulite 1000,Siemens-Immulite 2000,SQi Diagnostics-Sqidlite,SQi Diagnostics-Sqidworks,SQi Diagnostics-Sqid-X,Tecan-Infinite 200 PRO NanoQuant,Tecan-Infinite F200 PRO,Tecan-Infinite F50,Tecan-Infinite F500,Tecan-Infinite M1000 PRO,Tecan-Infinite M200,Tecan-Spark 10M,Tecan-Sunrise,Theradiag-CARIS,Theradiag-Chorus,Theradiag-FIDIS, Theradiag-Theralis µ,Theradiag-Theralis,Thermo Fisher-Fluoroskan Ascent,Thermo Fisher-Luminoskan Ascent,Thermo Fisher-Multiskan,Thermo Fisher-Phadia System 100,Thermo Fisher-Phadia System 1000,Thermo Fisher-Phadia System 250,Thermo Fisher-Phadia System 2500, Thermo Fisher-Phadia System 5000,Thermo Fisher-Varioskan Flash,Thermo Fisher-Varioskan LUX,Tosoh Corp-AIA-1800,Tosoh Corp-AIA-2000,Tosoh Corp-AIA-360,Tosoh Corp-AIA-600 II,Tosoh Corp-AIA-900,Transasia Bio-Medicals-Elan 30 s,Transasia Bio-Medicals-Erba Lisa Scan EM,Transasia Bio-Medicals-Erba Lisa Scan II,Transasia Bio-Medicals-Mago 4,VEDA.LAB-EASY READER 36100,Vircell S.L.-Dynex DS2 or any others.
Immunoassay Consumables Suppliers ++
Clinical & Research Use: End-users' current main suppliers of immunoassay consumables and those companies they anticipate will be supplying immunoassay consumables to their laboratories in three years from now, where the companies++ considered were 1 Step Detect Associates, Abbott Laboratories, Abcam, Access Bio, AccuBioTech, Accutech, ACON Laboratories, Aesku Diagnostics, Akers Biosciences, Akrivis Technologies, Alere, Alfa Scientific Designs, ALPCO, Alverix (BD), Amedica Biotech, American Bio Medica Corp, AmniSure (Qiagen), Ani Biotech Oy, Anjue, Audit Diagnostics, Augurex Life Sciences Corp, Autobio Diagnostics, Awareness Tech, AXA Diagnostics, Axela, Axis-Shield plc (Alere), AXO Science, BD, Beckman Coulter, Berthold, BG Medicine, Bhat Bio-Tech India, Binding Site Group, Biohit (BioHIt Healthcare), Biokit (Werfen Group), Biomerica, Biomerieux, BioPorto Diagnostics, Bio-Rad Laboratories, Bioscience Diag Tech, Biosensia, BioSystems International, Biotek, Biotron Diagnostics, BMG Labtech, Boditech Med, Bioserv Diagnostics, BSMED, Calypte Biomedical Corp, CardioGenics, CD Diagnostics, CerTest Biotec, CHINCAN, Cisbio Bioassays, Clarity Diagnostics, Clearbridge BioLoc, Clinical Innovations, Concateno (Alere), Confirm Biosciences, Core Life Sciences, Corgenix Medical, Coris BioConcept, Critical Diagnostics, CTK Biotech, Inc., Cytonics Corp, D & J, Danaher Corp, Denka Seiken, Devon Medical, DFI Co, diaDexus, DIALAB, Diamedix Corp, Diametra, DianGong, Diasorin, DIAsource ImmunoAssays, DiaSys Diagnostic Systems, DIESSE Diagnostica Senese, Dr. Fooke Laboratorien, DRG International, D-tek, Dynex, EDP Biotech Corp, EKF Diagnostics, Elite Medical, Epocal, ERBA Diagnostics, Euroimmun, First Check Diagnostics Corp, Fisher Scientific, Focus Diagnostics, FujiFilm, Fujirebio, Fullmedi, GE Healthcare, GeneFluidics, Germaine Laboratories, Getein Biotech, GlysBy, Gold Standard Diagnostics, Grifols, GY, Hamamatzu, Heales, HealthLinx Limited, Hema Diagnostic Systems, HemoCue, Hemosure, Hidex, Hightop, Hologic, Hycor, Idexx, IDS, IMMCO Diagnostics (Trinity), Immunetics, Immunodiagnostics, Immuno-Mycologics, InBios International, INOVA Diagnostics, InTec Products, International Immuno-Diagnostics, INV 100, Isogen Life Sciences, Jant Pharmacal Corp, Jei Daniel Biotech Corp, JOY JUN, JYbiotech, Kronus, LabLogic, Labon, Labor Diagnostika Nord, Labsystems Diagnostics, Landcom, Leica Biosystems, Lepud Medical, Leyte, Life technologies, LifeSign, Liming Bio-Products, LOSUN, Luminex Corp, MagnaBioSciences, Maroche, MAYA, MBio Diagnostics, MECAN, Molecular Devices, Molecular Diagnostics, OEM Systems, Olympus Diagnostics, Omega Diagnostics, OncoHealth Corp, Operon, OPKU Health, OraSure Technologies, Orgentec Diagnostika, Ortho Clinical, Pan Probe Biotech, Perfemed Group, Perkin elmer, Perlong, Pointe Scientific, Polymed Therapeutics, Polymedco, Preventis, Princeton Biomeditech, Pro-Lab Diagnostics, Protagen, Qiagen, Qualigen, Quanterix Corp, Radiometer Medical, Randox, Rapid Pathogen Screening, R-Biopharm AG, Readwell, Reagena Group, Real World Diagnostics, Response Biomedical Corp, Reszon Diagnostics, Roche Diagnostics, SA Scientific, Samsung, Savyon Diagnostics, ScheBo-Biotech, Sekisui Diagnostics, Shanghai Upper Biotech, Shenzhen New Industries, Siemens, Siloam Biosciences, SNIBE, SQi Diagnostics, Standard Diagnostics (Alere), SunShineMed, Sysmex Corp, Tecan, Theradiag, Thermo Fisher, Tosoh Corp, Transasia Bio-Medicals, Trinity Biotech, True Diagnostics, Turklab Medical Devices, UCP Biosciences, Urit Medical, US Diagnostics, Utrao, VEDA, Vircell, Vital Diagnostics (ELITech), Wako Diagnostics, WAMA Diagnostica and any others.
++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party
Market Size (Study Group)
As part of this study, end-users provided details of their immunoassy per-sample costs, together with the numbers of immunoassay runs they carry out on a monthly basis. These data allow an estimate of the annual market size corresponding to the running costs of immunoassay, associated with this group of 228 end-users. This is based on an average value of the per-sample costs and an average value for the number of sample runs per month. Purchasers of the Global License for this report are able to analyse these financial figures across all market sectors covered in this study. Also, these financial figures allow companies to estimate immunoassy 'running cost' market sizes on a global, regional or country-wide basis, from their own independent figures of the associated numbers of immunoassay users.
Immunoassay Applications
Clinical & Research Use: End-users' current main immunoassay applications used in their laboratories and those immunoassy applications they anticipate they will be using in their laboratories in three years from now, where the applications considered were Alcohol screening, Allergy, Anemia, Antiphospholipid Syndrome (APS), Autoimmune, Blood Borne, Blood Genotyping, Bone, Brain damages, Breast Care, Cancer markers, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Circulating Immuno Complexes, Coagulation, Complement, Connective Tissue, Critical Care, Diabetes, Drug Abuse Tests, Endocrinology, Fertility, FOB Tests, Food Intolerance, Gastrointestinal, Genetic, Growth Factors, Hepatitis, Hormones, Hypertension, Immunology Markers, Infections – Bacterial, Infections – Viral, Inflammation, Liver Disease, Metabolism, Misfolded Proteins, Neurodegenerative diseases, Neuroscience, Newborn screening, Obesity, Ovulation, Perinatal, Pregnancy, Primary Immunodeficiency (PID), Rheumatoid Arthritis, Saliva Drug Screens, Sepsis, Sexually Transmitted, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Urine Tests, Vascular disease, Vasculitis, Veterinary, Vitamin deficiencies, Women's Health and any others.
Multimplexing of Immunoassay
Clinical & Research Use: End-users' current levels of multiplexing of immunoassay and the levels of multiplexing of immunoassy they anticipate they will be using in their laboratories in three years from now, where the multiplexing levels considerted were 1 to 5, 6 to 10, 15/11/2015 00:00:00, 16-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-150, 151 – 200, > 200 and No Multiplex Assays.
Immunoassay Types
Clinical & Research Use: End-users' current main immunoassay types used in their laboratories and those immunoassy types they anticipate they will be using in their laboratories in three years from now, where the immunoassay types considered were ELISA – Enzyme Linked ImmunoSorbent Assay, RIA – Radio-ImmunoAssay, EMIT – Enzyme Multiplied Immunoassay, FRET – Fluorescent Resonance Energy Transfer, FPIA – Fluorescent Polarized Immunoassay, KIMS – Kinetic Interaction of Microparticles in Solution, CEDIA – Cloned Enzyme Donor Immunoassay, Lateral Flow Immunoassay and any others.
Immunoassay Formats
Clinical & Research Use: End-users' current main immunoassay formats used in their laboratories and those immunoassy formats they anticipate they will be using in their laboratories in three years from now, where the immunoassay formats considered were Competitive, homogeneous immunoassay; Competitive, heterogeneous immunoassay; One-site, noncompetitive immunoassay and Two-site, noncompetitive immunoassay and any others.
Immunoassay Labels
Clinical & Research Use: End-users' current main immunoassay labels used in their laboratories and those immunoassy labels they anticipate they will be using in their laboratories in three years from now, where the immunoassay labels considered were Enzymes, Radioactive isotopes, DNA reporters, Fluorogenic reporters, Electrochemiluminescent tags, Labeless immunoassays and any others.
Innovation and Development Needs
Clinical & Research: Based on their own experience, end-users' views on the areas of greatest need for innovation or development in immunoassay, where the areas considered were Accuracy, Ambiguities, Applicability to 'difficult' samples, Consistancy, Convenience, Cost, Data interpretation, Ease of use, Extraction times, Multiplex capabilities, Immunoassay run times, Reagent degradation, Reliability, Robustness, Safety, Sensitivity, Service support, Size footprint, Software capabilities, Speed, Stability, Throughput, Versatility and any other areas.
Assay Costs
End user's estimates of the average costs of their immunoassay analyses for a typical study sample in their laboratory, where the cost levels considered were <$5, $5 - $10, $10 - $20, $20 - $30, $30 - $40, $40 - $50, $50 - $70, $70 - $100, $100 - $150, $150 - $250, $250 - $400, $400 - $600, $600 - $1000 and > $1000.
Sample Throughput
End user's estimates of the average number of study samples they analyse each month using immunoassay in their laboratory, where the throughput levels considered were <10, 10 - 20, 20 – 30, 30 – 40, 40 – 50, 50 – 70, 70 – 100, 100 – 150, 150 – 250, 250- 400, 400 – 600, 600 – 1000, 1000 – 1500, 1500 – 2000, 2000 – 2500 and > 2500.
Relative Assay Cost Areas
Clinical & Research: In terms of relative costs, end-users own estimates (on a scale of 1 - 7) of the different relative cost levels associated with their immunoassay consumables, where 1 is the lowest relative cost and 7 in the highest and where the options evaluated were Immunoassay kits and reagents, External services costs, Instrument service (maintenance) contracts, Plasticware (tips, tubes etc), Sample preparation (extraction) kits and reagents, Software licenses and any other.
Immunoassay Fields
End-users' current main fields of use of immunoassay, where the fields considered were Biochemistry, Biology, Biotechnology, Clinical Therapeutics, Clinical Diagnostics, Environmental, Food & Drink, Forensics, Government, Healthcare, Medicine, Natural Products, Pharmaceuticals, Veterinary and any other.
Broad Applications of Immunoassay
End-users current main broad applications of their immunoassay and those main broad applications they anticipate in three years from now, where the broad applications considered were Clinical Therapeutics – Treatment Decisions; Clinical Therapeutics – Treatment Monitoring; Clinical Therapeutics – Clinical Trials; Clinical Therapeutics – Research; Diagnostics – Routine patient Tests; Diagnostics – Patient Screening; Diagnostics – Research; Diagnostics – Disease Biomarkers; Drug R&D – Discovery; Drug R&D – Drug Targets; Drug R&D – Preclinical studies; Drug R&D – ADME; Drug R&D – Toxicology; Drug R&D – Drug Metabolism; Drug R&D – Clinical Trials; Bioprocesses; Bacteriology; Cytology; Cytogenetics; Genomics; Metabolomics; Proteomics; Virology and any other.
Immunoassay Environment
End-user's main environment for the use of immunoassay, where the environments considered were Laboratory, Point of Care (POC), Blood Screening or any other.
Disease Biomarkers
The disease areas to which their immunoassay is used, where the diseases considered were Arthritis, Autoimmune Diseases, Bone Metabolism, Cancer, Cardiovascular, Central Nervous System, Dentistry, Dermatology, Endocrine, Gastrointestinal, Genito-urinary System, Haematology, Infections, Inflammation, Metabolic Disorders, Musculoskeletal Disorders, Nutrition, Obstetrics and Gynaecology, Ophthalmology, Pain, Psychiatry, Respiratory, Skin, any other or None.
The purpose of their immunoassay disease biomarker studies, where the purposes considered were Biomarker Discovery, Clinical – Research, Clinical – Trials, Diagnostics – Screening, Diagnostics – Research, Diagnostics – Routine tests, Disease research, Drug R&D – Clinical trials, Drug R&D – Drug targets, Drug R&D – Preclinical, Drug R&D – ADME, Toxicology, Treatment – Decisions, Treatment – Monitoring or any other.
The clinical utility of their immunoassay disease biomarker studies, where the options considered were Companion diagnostics, Disease prognosis, Disease stage or severity, Disease susceptibility or risk, Disease variability, Drug discovery, Drug therapy dose, Early detection of disease, Guiding treatment, Multiple utilities, Response to therapy, Safety or toxicity factors, Screening and monitoring, Therapy decision-making or other.
Participants
- Organisation Types: Immunoassay end-user's organisation type, where the options were Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation or other.
- Experience: End-users' years of experience using immunoassay
- Job Title: End-user's job title, role and main activities.
- Countries and Regions: Immunoassay end-user's countries and global regions; Asia, North America, South America, Africa (Sub-Saharan), Central America/Caribbean, Australia, New Zealand and Oceania and Middle East/North Africa/and Greater Arabia.
- Participants: Names and organisations.
CHAPTER 1. INTRODUCTION (P.21)
1.1. This Chapter
1.2. Background
1.3. Study details
CHAPTER 2. PARTICIPANTS (P.44)
2.1. This Chapter
2.2. Global Regions
Figure 2.1. Global regions of participants in IA 2015
Table 2.1. Global regions of participants in IA 2015
2.3. Countries
Figure 2.2. Top ten countries of participants in IA 2015
Table 2.2. Countries of participants in IA 2015
2.4. Job Titles
Figure 2.3. Job titles of participants in IA 2015
Table 2.3. Job titles of participants in IA 2015
2.5. Experience
Figure 2.4. Top ten experience levels of participants in IA 2015
Table 2.4. Experience of participants in IA 2015
2.6. Organisation Type
Figure 2.5. Organisation types of participants in IA 2015
Table 2.5. Organisation types of participants in IA 2015
2.7. Role
Figure 2.6. Roles of participants in IA 2015
Table 2.6. Roles of participants in IA 2015
CHAPTER 3. FIELDS (P.56)
3.1. This Chapter
3.2. Fields
Figure 3.1. Top ten main fields of participants in IA 2015, to which their immunoassay activities relate
Table 3.1. Main fields of participants in IA 2015, to which their immunoassay activities relate
CHAPTER 4. BROAD APPLICATIONS (P.59)
4.1. This Chapter
4.2. Current Broad Applications
Figure 4.1. Top ten main current broad applications of participants in IA 2015, to which their immunoassay activities relate
Table 4.1. Main current broad applications of participants in IA 2015, to which their immunoassay activities relate
4.3. Future Broad Applications
Figure 4.2. Top ten anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
Table 4.2. Main anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
4.4. Discussion
CHAPTER 5. MAIN IMMUNOASSAY AREAS (P.64)
5.1. This Chapter
5.2. Immunoassay Main Areas
Figure 5.1. The immunoassay main areas of IA 2015 participants
Table 5.1. The immunoassay main areas of IA 2015 participants
CHAPTER 6. RESEARCH OR CLINICAL (P.66)
6.1. This Chapter
6.2. Research or Clinical
Figure 6.1. The immunoassay areas of IA 2015 participants
Table 6.1. The immunoassay areas of IA 2015 participants
CHAPTER 7. IMMUNOASSAY IN RESEARCH (P.68)
7.1. This Chapter
7.2. Main Activities
Figure 7.1. The immunoassay activities of IA 2015 research participants
Table 7.1. The immunoassay activities of IA 2015 research participants
7.3. Current Immunoassay Formats
Figure 7.2. Current Immunoassay formats used by IA 2015 research participants
Table 7.2. Current Immunoassay formats used by IA 2015 research participants
7.4. Future Immunoassay Formats
Figure 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
Table 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
7.5. Current Immunoassay Labels
Figure 7.4. Current Immunoassay labels used by IA 2015 research participants
Table 7.4. Current Immunoassay labels used by IA 2015 research participants
7.6. Future Immunoassay Labels
Figure 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
Table 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
7.7. Current Immunoassay Types
Figure 7.6. Current Immunoassay types used by IA 2015 research participants
Table 7.6. Current Immunoassay types used by IA 2015 research participants
7.8. Future Immunoassay Types
Figure 7.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 7.7. Future Immunoassay types anticipated by IA 2015 research participants
7.9. Current Multiplex Assays
Figure 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
Table 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
7.10. Future Multiplex Assays
Figure 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
Table 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
7.11. Current Study Samples
Figure 7.10. Top ten current study samples analysed by IA 2015 research participants
Table 7.10. Current study samples analysed by IA 2015 research participants
7.12. Future Study Samples
Figure 7.11. Top ten future study samples anticipated by IA 2015 research participants
Table 7.11. Future study samples anticipated by IA 2015 research participants
7.13. Current Diseases
Figure 7.12. Top ten current diseases studied using immunoassay by IA 2015 research participants
Table 7.12. Current diseases studied using immunoassay by IA 2015 research participants
7.14. Future Diseases
Figure 7.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 research participants
Table 7.13. Future diseases anticipated to be studied using immunoassay by IA 2015 research participants
7.15. Current Immunoassay Applications
Figure 7.14. Current immunoassay applications of IA 2015 research participants
Table 7.14. Current immunoassay applications of IA 2015 research participants
7.16. Future Immunoassay Applications
Figure 7.15. Top ten anticipated future immunoassay applications of IA 2015 research participants
Table 7.15. Future anticipated immunoassay applications of IA 2015 research participants
7.17. Current Immunoassay Reader Suppliers
Figure 7.16. Top ten current immunoassay reader suppliers of IA 2015 research participants
Table 7.16. Current immunoassay reader suppliers of IA 2015 research participants
7.18. Future Immunoassay Reader Suppliers
Figure 7.17. Top ten anticipated future reader suppliers of IA 2015 research participants
Table 7.17. Anticipated future reader suppliers of IA 2015 research participants
7.19. Current Immunoassay Readers
Figure 7.18. Top ten current immunoassay readers of IA 2015 research participants
Table 7.18. Current immunoassay readers of IA 2015 research participants
7.20. Future Immunoassay Readers
Figure 7.19. Top ten anticipated future readers of IA 2015 research participants
Table 7.19. Anticipated future readers of IA 2015 research participants
7.21. Current Immunoassay Consumables Suppliers
Figure 7.20. Top ten current immunoassay consumables suppliers of IA 2015 research participants
Table 7.20. Current immunoassay consumables suppliers of IA 2015 research participants
7.22. Future Immunoassay Consumables Suppliers
Figure 7.21. Top ten anticipated future consumables suppliers of IA 2015 research participants
Table 7.21. Anticipated future consumables suppliers of IA 2015 research participants
7.23. Consumables Costs
Figure 7.22. Relative immunoassay costs of IA 2015 research participants
Table 7.22. Relative immunoassay costs of IA 2015 research participants
7.24. Needs or Innovation Requirements
Figure 7.23. Top ten immunoassay needs or innovation requirements of IA 2015 research participants
Table 7.23. Immunoassay needs or innovation requirements of IA 2015 research participants
CHAPTER 8. CLINICAL IMMUNOASSAY (P.104)
8.1. This Chapter
8.2. Main Activities
Figure 8.1. The immunoassay activities of IA 2015 clinical participants
Table 8.1. The immunoassay activities of IA 2015 clinical participants
8.3. Current Immunoassay Formats
Figure 8.2. Current Immunoassay formats used by IA 2015 clinical participants
Table 8.2. Current Immunoassay formats used by IA 2015 clinical participants
8.4. Future Immunoassay Formats
Figure 8.3. Future immunoassay formats anticipated by IA 2015 clinical participants
Table 8.3. Future Immunoassay formats anticipated by IA 2015 clinical participants
8.5. Current Immunoassay Labels
Figure 8.4. Current Immunoassay labels used by IA 2015 clinical participants
Table 8.4. Current Immunoassay labels used by IA 2015 clinical participants
8.6. Future Immunoassay Labels
Figure 8.5. Future Immunoassay labels anticipated by IA 2015 Clinical participants
Table 8.5. Future Immunoassay labels anticipated by IA 2015 clinical participants
8.7. Current Immunoassay Types
Figure 8.6. Current Immunoassay types used by IA 2015 clinical participants
Table 8.6. Current Immunoassay types used by IA 2015 clinical participants
8.8. Future Immunoassay Types
Figure 8.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 8.7. Future Immunoassay types anticipated by IA 2015 clinical participants
8.9. Current Multiplex Assays
Figure 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
8.10. Future Multiplex Assays
Figure 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
8.11. Current Study Samples
Figure 8.10. Top ten current study samples analysed by IA 2015 clinical participants
Table 8.10. Top ten current study samples analysed by IA 2015 clinical participants
8.12. Future Study Samples
Figure 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
Table 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
8.13. Current Diseases
Figure 8.12. Top ten current diseases studied using immunoassay by IA 2015 clinical participants
Table 8.12. Current diseases studied using immunoassay by IA 2015 participants
8.14. Future Diseases
Figure 8.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
Table 8.13. Future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
8.15. Current Immunoassay Applications
Figure 8.14. Top ten current immunoassay applications of IA 2015 clinical participants
Table 8.14. Top ten current immunoassay applications of IA 2015 clinical participants8.16. Future Immunoassay Applications
8.16. Future Immunoassay Applications
Figure 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
Table 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
8.17. Current Immunoassay Reader Suppliers
Figure 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
Table 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
8.18. Current Immunoassay Reader Suppliers
Figure 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
Table 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
8.19. Current Immunoassay Readers
Figure 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
Table 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
8.20. Future Immunoassay Readers
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
8.21. Current Immunoassay Consumables Suppliers
Figure 8.20. Top ten current immunoassay consumables suppliers of IA 2015 clinical participants
Table 8.20. Current immunoassay consumables suppliers of IA 2015 clinical participants
8.22. Future Immunoassay Consumables Suppliers
Figure 8.21. Top ten anticipated future consumables suppliers of IA 2015 clinical participants
Table 8.21. Anticipated future consumables suppliers of IA 2015 clinical participants
8.23. Consumables Costs
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
8.24. Needs or Innovation Requirements
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
CHAPTER 9. IMMUNOASSAY GROWTH TRENDS (P.146)
9.1. This Chapter
9.2. Recent Growth Trends
Figure 9.1. Top ten recent growth levels in the use of immunoassay, indicated by IA 2015 participants
Table 9.1. Recent growth levels in the use of immunoassay, indicated by IA 2015 participants
9.3. Future Growth Trends
Figure 9.2. Top ten growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
Table 9.2. Growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
CHAPTER 10. DISEASE BIOMARKERS (P.150)
10.1. This Chapter
10.2. Biomarker Disease Areas
Figure 10.1. Top disease areas to which IA 2015 participant's immunoassay biomarker studies relate
Table 10.1. Disease areas to which IA 2015 participant's immunoassay biomarker studies relate
10.3. Purposes of immunoassay Biomarker Studies
Figure 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
Table 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
10.4. Clinical Utility of immunoassay Disease Biomarkers
Figure 10.3. Top clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
Table 10.3. Clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
CHAPTER 11. COSTS (P.155)
11.1. This Chapter
11.2. Costs
Figure 11.1. Top per-sample costs levels using immunoassay, indicated by IA 2015 participants
Table 11.1. Per-sample costs levels using immunoassay, indicated by IA 2015 participants
CHAPTER 12. SAMPLE THROUGHPUT (P.158)
12.1. This Chapter
12.2. Sample Throughput
Figure 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
Table 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
CHAPTER 13. DISCUSSION (P.161)
13.1. Discussion@Chapter 1. Introduction (p.21)
1.1. This Chapter
1.2. Background
1.3. Study details
CHAPTER 2. PARTICIPANTS (P.44)
2.1. This Chapter
2.2. Global Regions
Figure 2.1. Global regions of participants in IA 2015
Table 2.1. Global regions of participants in IA 2015
2.3. Countries
Figure 2.2. Top ten countries of participants in IA 2015
Table 2.2. Countries of participants in IA 2015
2.4. Job Titles
Figure 2.3. Job titles of participants in IA 2015
Table 2.3. Job titles of participants in IA 2015
2.5. Experience
Figure 2.4. Top ten experience levels of participants in IA 2015
Table 2.4. Experience of participants in IA 2015
2.6. Organisation Type
Figure 2.5. Organisation types of participants in IA 2015
Table 2.5. Organisation types of participants in IA 2015
2.7. Role
Figure 2.6. Roles of participants in IA 2015
Table 2.6. Roles of participants in IA 2015
CHAPTER 3. FIELDS (P.56)
3.1. This Chapter
3.2. Fields
Figure 3.1. Top ten main fields of participants in IA 2015, to which their immunoassay activities relate
Table 3.1. Main fields of participants in IA 2015, to which their immunoassay activities relate
CHAPTER 4. BROAD APPLICATIONS (P.59)
4.1. This Chapter
4.2. Current Broad Applications
Figure 4.1. Top ten main current broad applications of participants in IA 2015, to which their immunoassay activities relate
Table 4.1. Main current broad applications of participants in IA 2015, to which their immunoassay activities relate
4.3. Future Broad Applications
Figure 4.2. Top ten anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
Table 4.2. Main anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
4.4. Discussion
CHAPTER 5. MAIN IMMUNOASSAY AREAS (P.64)
5.1. This Chapter
5.2. Immunoassay Main Areas
Figure 5.1. The immunoassay main areas of IA 2015 participants
Table 5.1. The immunoassay main areas of IA 2015 participants
CHAPTER 6. RESEARCH OR CLINICAL (P.66)
6.1. This Chapter
6.2. Research or Clinical
Figure 6.1. The immunoassay areas of IA 2015 participants
Table 6.1. The immunoassay areas of IA 2015 participants
CHAPTER 7. IMMUNOASSAY IN RESEARCH (P.68)
7.1. This Chapter
7.2. Main Activities
Figure 7.1. The immunoassay activities of IA 2015 research participants
Table 7.1. The immunoassay activities of IA 2015 research participants
7.3. Current Immunoassay Formats
Figure 7.2. Current Immunoassay formats used by IA 2015 research participants
Table 7.2. Current Immunoassay formats used by IA 2015 research participants
7.4. Future Immunoassay Formats
Figure 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
Table 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
7.5. Current Immunoassay Labels
Figure 7.4. Current Immunoassay labels used by IA 2015 research participants
Table 7.4. Current Immunoassay labels used by IA 2015 research participants
7.6. Future Immunoassay Labels
Figure 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
Table 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
7.7. Current Immunoassay Types
Figure 7.6. Current Immunoassay types used by IA 2015 research participants
Table 7.6. Current Immunoassay types used by IA 2015 research participants
7.8. Future Immunoassay Types
Figure 7.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 7.7. Future Immunoassay types anticipated by IA 2015 research participants
7.9. Current Multiplex Assays
Figure 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
Table 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
7.10. Future Multiplex Assays
Figure 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
Table 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
7.11. Current Study Samples
Figure 7.10. Top ten current study samples analysed by IA 2015 research participants
Table 7.10. Current study samples analysed by IA 2015 research participants
7.12. Future Study Samples
Figure 7.11. Top ten future study samples anticipated by IA 2015 research participants
Table 7.11. Future study samples anticipated by IA 2015 research participants
7.13. Current Diseases
Figure 7.12. Top ten current diseases studied using immunoassay by IA 2015 research participants
Table 7.12. Current diseases studied using immunoassay by IA 2015 research participants
7.14. Future Diseases
Figure 7.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 research participants
Table 7.13. Future diseases anticipated to be studied using immunoassay by IA 2015 research participants
7.15. Current Immunoassay Applications
Figure 7.14. Current immunoassay applications of IA 2015 research participants
Table 7.14. Current immunoassay applications of IA 2015 research participants
7.16. Future Immunoassay Applications
Figure 7.15. Top ten anticipated future immunoassay applications of IA 2015 research participants
Table 7.15. Future anticipated immunoassay applications of IA 2015 research participants
7.17. Current Immunoassay Reader Suppliers
Figure 7.16. Top ten current immunoassay reader suppliers of IA 2015 research participants
Table 7.16. Current immunoassay reader suppliers of IA 2015 research participants
7.18. Future Immunoassay Reader Suppliers
Figure 7.17. Top ten anticipated future reader suppliers of IA 2015 research participants
Table 7.17. Anticipated future reader suppliers of IA 2015 research participants
7.19. Current Immunoassay Readers
Figure 7.18. Top ten current immunoassay readers of IA 2015 research participants
Table 7.18. Current immunoassay readers of IA 2015 research participants
7.20. Future Immunoassay Readers
Figure 7.19. Top ten anticipated future readers of IA 2015 research participants
Table 7.19. Anticipated future readers of IA 2015 research participants
7.21. Current Immunoassay Consumables Suppliers
Figure 7.20. Top ten current immunoassay consumables suppliers of IA 2015 research participants
Table 7.20. Current immunoassay consumables suppliers of IA 2015 research participants
7.22. Future Immunoassay Consumables Suppliers
Figure 7.21. Top ten anticipated future consumables suppliers of IA 2015 research participants
Table 7.21. Anticipated future consumables suppliers of IA 2015 research participants
7.23. Consumables Costs
Figure 7.22. Relative immunoassay costs of IA 2015 research participants
Table 7.22. Relative immunoassay costs of IA 2015 research participants
7.24. Needs or Innovation Requirements
Figure 7.23. Top ten immunoassay needs or innovation requirements of IA 2015 research participants
Table 7.23. Immunoassay needs or innovation requirements of IA 2015 research participants
CHAPTER 8. CLINICAL IMMUNOASSAY (P.104)
8.1. This Chapter
8.2. Main Activities
Figure 8.1. The immunoassay activities of IA 2015 clinical participants
Table 8.1. The immunoassay activities of IA 2015 clinical participants
8.3. Current Immunoassay Formats
Figure 8.2. Current Immunoassay formats used by IA 2015 clinical participants
Table 8.2. Current Immunoassay formats used by IA 2015 clinical participants
8.4. Future Immunoassay Formats
Figure 8.3. Future immunoassay formats anticipated by IA 2015 clinical participants
Table 8.3. Future Immunoassay formats anticipated by IA 2015 clinical participants
8.5. Current Immunoassay Labels
Figure 8.4. Current Immunoassay labels used by IA 2015 clinical participants
Table 8.4. Current Immunoassay labels used by IA 2015 clinical participants
8.6. Future Immunoassay Labels
Figure 8.5. Future Immunoassay labels anticipated by IA 2015 Clinical participants
Table 8.5. Future Immunoassay labels anticipated by IA 2015 clinical participants
8.7. Current Immunoassay Types
Figure 8.6. Current Immunoassay types used by IA 2015 clinical participants
Table 8.6. Current Immunoassay types used by IA 2015 clinical participants
8.8. Future Immunoassay Types
Figure 8.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 8.7. Future Immunoassay types anticipated by IA 2015 clinical participants
8.9. Current Multiplex Assays
Figure 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
8.10. Future Multiplex Assays
Figure 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
8.11. Current Study Samples
Figure 8.10. Top ten current study samples analysed by IA 2015 clinical participants
Table 8.10. Top ten current study samples analysed by IA 2015 clinical participants
8.12. Future Study Samples
Figure 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
Table 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
8.13. Current Diseases
Figure 8.12. Top ten current diseases studied using immunoassay by IA 2015 clinical participants
Table 8.12. Current diseases studied using immunoassay by IA 2015 participants
8.14. Future Diseases
Figure 8.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
Table 8.13. Future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
8.15. Current Immunoassay Applications
Figure 8.14. Top ten current immunoassay applications of IA 2015 clinical participants
Table 8.14. Top ten current immunoassay applications of IA 2015 clinical participants8.16. Future Immunoassay Applications
8.16. Future Immunoassay Applications
Figure 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
Table 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
8.17. Current Immunoassay Reader Suppliers
Figure 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
Table 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
8.18. Current Immunoassay Reader Suppliers
Figure 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
Table 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
8.19. Current Immunoassay Readers
Figure 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
Table 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
8.20. Future Immunoassay Readers
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
8.21. Current Immunoassay Consumables Suppliers
Figure 8.20. Top ten current immunoassay consumables suppliers of IA 2015 clinical participants
Table 8.20. Current immunoassay consumables suppliers of IA 2015 clinical participants
8.22. Future Immunoassay Consumables Suppliers
Figure 8.21. Top ten anticipated future consumables suppliers of IA 2015 clinical participants
Table 8.21. Anticipated future consumables suppliers of IA 2015 clinical participants
8.23. Consumables Costs
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
8.24. Needs or Innovation Requirements
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
CHAPTER 9. IMMUNOASSAY GROWTH TRENDS (P.146)
9.1. This Chapter
9.2. Recent Growth Trends
Figure 9.1. Top ten recent growth levels in the use of immunoassay, indicated by IA 2015 participants
Table 9.1. Recent growth levels in the use of immunoassay, indicated by IA 2015 participants
9.3. Future Growth Trends
Figure 9.2. Top ten growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
Table 9.2. Growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
CHAPTER 10. DISEASE BIOMARKERS (P.150)
10.1. This Chapter
10.2. Biomarker Disease Areas
Figure 10.1. Top disease areas to which IA 2015 participant's immunoassay biomarker studies relate
Table 10.1. Disease areas to which IA 2015 participant's immunoassay biomarker studies relate
10.3. Purposes of immunoassay Biomarker Studies
Figure 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
Table 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
10.4. Clinical Utility of immunoassay Disease Biomarkers
Figure 10.3. Top clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
Table 10.3. Clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
CHAPTER 11. COSTS (P.155)
11.1. This Chapter
11.2. Costs
Figure 11.1. Top per-sample costs levels using immunoassay, indicated by IA 2015 participants
Table 11.1. Per-sample costs levels using immunoassay, indicated by IA 2015 participants
CHAPTER 12. SAMPLE THROUGHPUT (P.158)
12.1. This Chapter
12.2. Sample Throughput
Figure 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
Table 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
CHAPTER 13. DISCUSSION (P.161)
13.1. Discussion
1.1. This Chapter
1.2. Background
1.3. Study details
CHAPTER 2. PARTICIPANTS (P.44)
2.1. This Chapter
2.2. Global Regions
Figure 2.1. Global regions of participants in IA 2015
Table 2.1. Global regions of participants in IA 2015
2.3. Countries
Figure 2.2. Top ten countries of participants in IA 2015
Table 2.2. Countries of participants in IA 2015
2.4. Job Titles
Figure 2.3. Job titles of participants in IA 2015
Table 2.3. Job titles of participants in IA 2015
2.5. Experience
Figure 2.4. Top ten experience levels of participants in IA 2015
Table 2.4. Experience of participants in IA 2015
2.6. Organisation Type
Figure 2.5. Organisation types of participants in IA 2015
Table 2.5. Organisation types of participants in IA 2015
2.7. Role
Figure 2.6. Roles of participants in IA 2015
Table 2.6. Roles of participants in IA 2015
CHAPTER 3. FIELDS (P.56)
3.1. This Chapter
3.2. Fields
Figure 3.1. Top ten main fields of participants in IA 2015, to which their immunoassay activities relate
Table 3.1. Main fields of participants in IA 2015, to which their immunoassay activities relate
CHAPTER 4. BROAD APPLICATIONS (P.59)
4.1. This Chapter
4.2. Current Broad Applications
Figure 4.1. Top ten main current broad applications of participants in IA 2015, to which their immunoassay activities relate
Table 4.1. Main current broad applications of participants in IA 2015, to which their immunoassay activities relate
4.3. Future Broad Applications
Figure 4.2. Top ten anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
Table 4.2. Main anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
4.4. Discussion
CHAPTER 5. MAIN IMMUNOASSAY AREAS (P.64)
5.1. This Chapter
5.2. Immunoassay Main Areas
Figure 5.1. The immunoassay main areas of IA 2015 participants
Table 5.1. The immunoassay main areas of IA 2015 participants
CHAPTER 6. RESEARCH OR CLINICAL (P.66)
6.1. This Chapter
6.2. Research or Clinical
Figure 6.1. The immunoassay areas of IA 2015 participants
Table 6.1. The immunoassay areas of IA 2015 participants
CHAPTER 7. IMMUNOASSAY IN RESEARCH (P.68)
7.1. This Chapter
7.2. Main Activities
Figure 7.1. The immunoassay activities of IA 2015 research participants
Table 7.1. The immunoassay activities of IA 2015 research participants
7.3. Current Immunoassay Formats
Figure 7.2. Current Immunoassay formats used by IA 2015 research participants
Table 7.2. Current Immunoassay formats used by IA 2015 research participants
7.4. Future Immunoassay Formats
Figure 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
Table 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
7.5. Current Immunoassay Labels
Figure 7.4. Current Immunoassay labels used by IA 2015 research participants
Table 7.4. Current Immunoassay labels used by IA 2015 research participants
7.6. Future Immunoassay Labels
Figure 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
Table 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
7.7. Current Immunoassay Types
Figure 7.6. Current Immunoassay types used by IA 2015 research participants
Table 7.6. Current Immunoassay types used by IA 2015 research participants
7.8. Future Immunoassay Types
Figure 7.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 7.7. Future Immunoassay types anticipated by IA 2015 research participants
7.9. Current Multiplex Assays
Figure 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
Table 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
7.10. Future Multiplex Assays
Figure 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
Table 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
7.11. Current Study Samples
Figure 7.10. Top ten current study samples analysed by IA 2015 research participants
Table 7.10. Current study samples analysed by IA 2015 research participants
7.12. Future Study Samples
Figure 7.11. Top ten future study samples anticipated by IA 2015 research participants
Table 7.11. Future study samples anticipated by IA 2015 research participants
7.13. Current Diseases
Figure 7.12. Top ten current diseases studied using immunoassay by IA 2015 research participants
Table 7.12. Current diseases studied using immunoassay by IA 2015 research participants
7.14. Future Diseases
Figure 7.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 research participants
Table 7.13. Future diseases anticipated to be studied using immunoassay by IA 2015 research participants
7.15. Current Immunoassay Applications
Figure 7.14. Current immunoassay applications of IA 2015 research participants
Table 7.14. Current immunoassay applications of IA 2015 research participants
7.16. Future Immunoassay Applications
Figure 7.15. Top ten anticipated future immunoassay applications of IA 2015 research participants
Table 7.15. Future anticipated immunoassay applications of IA 2015 research participants
7.17. Current Immunoassay Reader Suppliers
Figure 7.16. Top ten current immunoassay reader suppliers of IA 2015 research participants
Table 7.16. Current immunoassay reader suppliers of IA 2015 research participants
7.18. Future Immunoassay Reader Suppliers
Figure 7.17. Top ten anticipated future reader suppliers of IA 2015 research participants
Table 7.17. Anticipated future reader suppliers of IA 2015 research participants
7.19. Current Immunoassay Readers
Figure 7.18. Top ten current immunoassay readers of IA 2015 research participants
Table 7.18. Current immunoassay readers of IA 2015 research participants
7.20. Future Immunoassay Readers
Figure 7.19. Top ten anticipated future readers of IA 2015 research participants
Table 7.19. Anticipated future readers of IA 2015 research participants
7.21. Current Immunoassay Consumables Suppliers
Figure 7.20. Top ten current immunoassay consumables suppliers of IA 2015 research participants
Table 7.20. Current immunoassay consumables suppliers of IA 2015 research participants
7.22. Future Immunoassay Consumables Suppliers
Figure 7.21. Top ten anticipated future consumables suppliers of IA 2015 research participants
Table 7.21. Anticipated future consumables suppliers of IA 2015 research participants
7.23. Consumables Costs
Figure 7.22. Relative immunoassay costs of IA 2015 research participants
Table 7.22. Relative immunoassay costs of IA 2015 research participants
7.24. Needs or Innovation Requirements
Figure 7.23. Top ten immunoassay needs or innovation requirements of IA 2015 research participants
Table 7.23. Immunoassay needs or innovation requirements of IA 2015 research participants
CHAPTER 8. CLINICAL IMMUNOASSAY (P.104)
8.1. This Chapter
8.2. Main Activities
Figure 8.1. The immunoassay activities of IA 2015 clinical participants
Table 8.1. The immunoassay activities of IA 2015 clinical participants
8.3. Current Immunoassay Formats
Figure 8.2. Current Immunoassay formats used by IA 2015 clinical participants
Table 8.2. Current Immunoassay formats used by IA 2015 clinical participants
8.4. Future Immunoassay Formats
Figure 8.3. Future immunoassay formats anticipated by IA 2015 clinical participants
Table 8.3. Future Immunoassay formats anticipated by IA 2015 clinical participants
8.5. Current Immunoassay Labels
Figure 8.4. Current Immunoassay labels used by IA 2015 clinical participants
Table 8.4. Current Immunoassay labels used by IA 2015 clinical participants
8.6. Future Immunoassay Labels
Figure 8.5. Future Immunoassay labels anticipated by IA 2015 Clinical participants
Table 8.5. Future Immunoassay labels anticipated by IA 2015 clinical participants
8.7. Current Immunoassay Types
Figure 8.6. Current Immunoassay types used by IA 2015 clinical participants
Table 8.6. Current Immunoassay types used by IA 2015 clinical participants
8.8. Future Immunoassay Types
Figure 8.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 8.7. Future Immunoassay types anticipated by IA 2015 clinical participants
8.9. Current Multiplex Assays
Figure 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
8.10. Future Multiplex Assays
Figure 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
8.11. Current Study Samples
Figure 8.10. Top ten current study samples analysed by IA 2015 clinical participants
Table 8.10. Top ten current study samples analysed by IA 2015 clinical participants
8.12. Future Study Samples
Figure 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
Table 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
8.13. Current Diseases
Figure 8.12. Top ten current diseases studied using immunoassay by IA 2015 clinical participants
Table 8.12. Current diseases studied using immunoassay by IA 2015 participants
8.14. Future Diseases
Figure 8.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
Table 8.13. Future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
8.15. Current Immunoassay Applications
Figure 8.14. Top ten current immunoassay applications of IA 2015 clinical participants
Table 8.14. Top ten current immunoassay applications of IA 2015 clinical participants8.16. Future Immunoassay Applications
8.16. Future Immunoassay Applications
Figure 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
Table 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
8.17. Current Immunoassay Reader Suppliers
Figure 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
Table 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
8.18. Current Immunoassay Reader Suppliers
Figure 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
Table 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
8.19. Current Immunoassay Readers
Figure 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
Table 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
8.20. Future Immunoassay Readers
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
8.21. Current Immunoassay Consumables Suppliers
Figure 8.20. Top ten current immunoassay consumables suppliers of IA 2015 clinical participants
Table 8.20. Current immunoassay consumables suppliers of IA 2015 clinical participants
8.22. Future Immunoassay Consumables Suppliers
Figure 8.21. Top ten anticipated future consumables suppliers of IA 2015 clinical participants
Table 8.21. Anticipated future consumables suppliers of IA 2015 clinical participants
8.23. Consumables Costs
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
8.24. Needs or Innovation Requirements
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
CHAPTER 9. IMMUNOASSAY GROWTH TRENDS (P.146)
9.1. This Chapter
9.2. Recent Growth Trends
Figure 9.1. Top ten recent growth levels in the use of immunoassay, indicated by IA 2015 participants
Table 9.1. Recent growth levels in the use of immunoassay, indicated by IA 2015 participants
9.3. Future Growth Trends
Figure 9.2. Top ten growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
Table 9.2. Growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
CHAPTER 10. DISEASE BIOMARKERS (P.150)
10.1. This Chapter
10.2. Biomarker Disease Areas
Figure 10.1. Top disease areas to which IA 2015 participant's immunoassay biomarker studies relate
Table 10.1. Disease areas to which IA 2015 participant's immunoassay biomarker studies relate
10.3. Purposes of immunoassay Biomarker Studies
Figure 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
Table 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
10.4. Clinical Utility of immunoassay Disease Biomarkers
Figure 10.3. Top clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
Table 10.3. Clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
CHAPTER 11. COSTS (P.155)
11.1. This Chapter
11.2. Costs
Figure 11.1. Top per-sample costs levels using immunoassay, indicated by IA 2015 participants
Table 11.1. Per-sample costs levels using immunoassay, indicated by IA 2015 participants
CHAPTER 12. SAMPLE THROUGHPUT (P.158)
12.1. This Chapter
12.2. Sample Throughput
Figure 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
Table 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
CHAPTER 13. DISCUSSION (P.161)
13.1. Discussion@Chapter 1. Introduction (p.21)
1.1. This Chapter
1.2. Background
1.3. Study details
CHAPTER 2. PARTICIPANTS (P.44)
2.1. This Chapter
2.2. Global Regions
Figure 2.1. Global regions of participants in IA 2015
Table 2.1. Global regions of participants in IA 2015
2.3. Countries
Figure 2.2. Top ten countries of participants in IA 2015
Table 2.2. Countries of participants in IA 2015
2.4. Job Titles
Figure 2.3. Job titles of participants in IA 2015
Table 2.3. Job titles of participants in IA 2015
2.5. Experience
Figure 2.4. Top ten experience levels of participants in IA 2015
Table 2.4. Experience of participants in IA 2015
2.6. Organisation Type
Figure 2.5. Organisation types of participants in IA 2015
Table 2.5. Organisation types of participants in IA 2015
2.7. Role
Figure 2.6. Roles of participants in IA 2015
Table 2.6. Roles of participants in IA 2015
CHAPTER 3. FIELDS (P.56)
3.1. This Chapter
3.2. Fields
Figure 3.1. Top ten main fields of participants in IA 2015, to which their immunoassay activities relate
Table 3.1. Main fields of participants in IA 2015, to which their immunoassay activities relate
CHAPTER 4. BROAD APPLICATIONS (P.59)
4.1. This Chapter
4.2. Current Broad Applications
Figure 4.1. Top ten main current broad applications of participants in IA 2015, to which their immunoassay activities relate
Table 4.1. Main current broad applications of participants in IA 2015, to which their immunoassay activities relate
4.3. Future Broad Applications
Figure 4.2. Top ten anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
Table 4.2. Main anticipated future main broad fields of participants in IA 2015, to which their immunoassay activities relate
4.4. Discussion
CHAPTER 5. MAIN IMMUNOASSAY AREAS (P.64)
5.1. This Chapter
5.2. Immunoassay Main Areas
Figure 5.1. The immunoassay main areas of IA 2015 participants
Table 5.1. The immunoassay main areas of IA 2015 participants
CHAPTER 6. RESEARCH OR CLINICAL (P.66)
6.1. This Chapter
6.2. Research or Clinical
Figure 6.1. The immunoassay areas of IA 2015 participants
Table 6.1. The immunoassay areas of IA 2015 participants
CHAPTER 7. IMMUNOASSAY IN RESEARCH (P.68)
7.1. This Chapter
7.2. Main Activities
Figure 7.1. The immunoassay activities of IA 2015 research participants
Table 7.1. The immunoassay activities of IA 2015 research participants
7.3. Current Immunoassay Formats
Figure 7.2. Current Immunoassay formats used by IA 2015 research participants
Table 7.2. Current Immunoassay formats used by IA 2015 research participants
7.4. Future Immunoassay Formats
Figure 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
Table 7.3. Future Immunoassay formats anticipated by IA 2015 research participants
7.5. Current Immunoassay Labels
Figure 7.4. Current Immunoassay labels used by IA 2015 research participants
Table 7.4. Current Immunoassay labels used by IA 2015 research participants
7.6. Future Immunoassay Labels
Figure 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
Table 7.5. Future Immunoassay labels anticipated by IA 2015 research participants
7.7. Current Immunoassay Types
Figure 7.6. Current Immunoassay types used by IA 2015 research participants
Table 7.6. Current Immunoassay types used by IA 2015 research participants
7.8. Future Immunoassay Types
Figure 7.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 7.7. Future Immunoassay types anticipated by IA 2015 research participants
7.9. Current Multiplex Assays
Figure 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
Table 7.8. Current immunoassay multiplexing levels of IA 2015 research participants
7.10. Future Multiplex Assays
Figure 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
Table 7.9. Future immunoassay multiplexing levels of IA 2015 research participants
7.11. Current Study Samples
Figure 7.10. Top ten current study samples analysed by IA 2015 research participants
Table 7.10. Current study samples analysed by IA 2015 research participants
7.12. Future Study Samples
Figure 7.11. Top ten future study samples anticipated by IA 2015 research participants
Table 7.11. Future study samples anticipated by IA 2015 research participants
7.13. Current Diseases
Figure 7.12. Top ten current diseases studied using immunoassay by IA 2015 research participants
Table 7.12. Current diseases studied using immunoassay by IA 2015 research participants
7.14. Future Diseases
Figure 7.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 research participants
Table 7.13. Future diseases anticipated to be studied using immunoassay by IA 2015 research participants
7.15. Current Immunoassay Applications
Figure 7.14. Current immunoassay applications of IA 2015 research participants
Table 7.14. Current immunoassay applications of IA 2015 research participants
7.16. Future Immunoassay Applications
Figure 7.15. Top ten anticipated future immunoassay applications of IA 2015 research participants
Table 7.15. Future anticipated immunoassay applications of IA 2015 research participants
7.17. Current Immunoassay Reader Suppliers
Figure 7.16. Top ten current immunoassay reader suppliers of IA 2015 research participants
Table 7.16. Current immunoassay reader suppliers of IA 2015 research participants
7.18. Future Immunoassay Reader Suppliers
Figure 7.17. Top ten anticipated future reader suppliers of IA 2015 research participants
Table 7.17. Anticipated future reader suppliers of IA 2015 research participants
7.19. Current Immunoassay Readers
Figure 7.18. Top ten current immunoassay readers of IA 2015 research participants
Table 7.18. Current immunoassay readers of IA 2015 research participants
7.20. Future Immunoassay Readers
Figure 7.19. Top ten anticipated future readers of IA 2015 research participants
Table 7.19. Anticipated future readers of IA 2015 research participants
7.21. Current Immunoassay Consumables Suppliers
Figure 7.20. Top ten current immunoassay consumables suppliers of IA 2015 research participants
Table 7.20. Current immunoassay consumables suppliers of IA 2015 research participants
7.22. Future Immunoassay Consumables Suppliers
Figure 7.21. Top ten anticipated future consumables suppliers of IA 2015 research participants
Table 7.21. Anticipated future consumables suppliers of IA 2015 research participants
7.23. Consumables Costs
Figure 7.22. Relative immunoassay costs of IA 2015 research participants
Table 7.22. Relative immunoassay costs of IA 2015 research participants
7.24. Needs or Innovation Requirements
Figure 7.23. Top ten immunoassay needs or innovation requirements of IA 2015 research participants
Table 7.23. Immunoassay needs or innovation requirements of IA 2015 research participants
CHAPTER 8. CLINICAL IMMUNOASSAY (P.104)
8.1. This Chapter
8.2. Main Activities
Figure 8.1. The immunoassay activities of IA 2015 clinical participants
Table 8.1. The immunoassay activities of IA 2015 clinical participants
8.3. Current Immunoassay Formats
Figure 8.2. Current Immunoassay formats used by IA 2015 clinical participants
Table 8.2. Current Immunoassay formats used by IA 2015 clinical participants
8.4. Future Immunoassay Formats
Figure 8.3. Future immunoassay formats anticipated by IA 2015 clinical participants
Table 8.3. Future Immunoassay formats anticipated by IA 2015 clinical participants
8.5. Current Immunoassay Labels
Figure 8.4. Current Immunoassay labels used by IA 2015 clinical participants
Table 8.4. Current Immunoassay labels used by IA 2015 clinical participants
8.6. Future Immunoassay Labels
Figure 8.5. Future Immunoassay labels anticipated by IA 2015 Clinical participants
Table 8.5. Future Immunoassay labels anticipated by IA 2015 clinical participants
8.7. Current Immunoassay Types
Figure 8.6. Current Immunoassay types used by IA 2015 clinical participants
Table 8.6. Current Immunoassay types used by IA 2015 clinical participants
8.8. Future Immunoassay Types
Figure 8.7. Future Immunoassay types anticipated by IA 2015 research participants
Table 8.7. Future Immunoassay types anticipated by IA 2015 clinical participants
8.9. Current Multiplex Assays
Figure 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.8. Current immunoassay multiplexing levels of IA 2015 clinical participants
8.10. Future Multiplex Assays
Figure 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
Table 8.9. Future immunoassay multiplexing levels of IA 2015 clinical participants
8.11. Current Study Samples
Figure 8.10. Top ten current study samples analysed by IA 2015 clinical participants
Table 8.10. Top ten current study samples analysed by IA 2015 clinical participants
8.12. Future Study Samples
Figure 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
Table 8.11. Top ten future study samples anticipated by IA 2015 clinical participants
8.13. Current Diseases
Figure 8.12. Top ten current diseases studied using immunoassay by IA 2015 clinical participants
Table 8.12. Current diseases studied using immunoassay by IA 2015 participants
8.14. Future Diseases
Figure 8.13. Top ten future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
Table 8.13. Future diseases anticipated to be studied using immunoassay by IA 2015 clinical participants
8.15. Current Immunoassay Applications
Figure 8.14. Top ten current immunoassay applications of IA 2015 clinical participants
Table 8.14. Top ten current immunoassay applications of IA 2015 clinical participants8.16. Future Immunoassay Applications
8.16. Future Immunoassay Applications
Figure 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
Table 8.15. Top ten anticipated future immunoassay applications of IA 2015 Clinical participants
8.17. Current Immunoassay Reader Suppliers
Figure 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
Table 8.16. Top ten current immunoassay reader suppliers of IA 2015 clinical participants
8.18. Current Immunoassay Reader Suppliers
Figure 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
Table 8.17. Top ten anticipated future reader suppliers of IA 2015 clinical participants
8.19. Current Immunoassay Readers
Figure 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
Table 8.18. Top ten current immunoassay readers of IA 2015 clinical participants
8.20. Future Immunoassay Readers
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
Figure 8.19. Top ten anticipated future readers of IA 2015 clinical participants
8.21. Current Immunoassay Consumables Suppliers
Figure 8.20. Top ten current immunoassay consumables suppliers of IA 2015 clinical participants
Table 8.20. Current immunoassay consumables suppliers of IA 2015 clinical participants
8.22. Future Immunoassay Consumables Suppliers
Figure 8.21. Top ten anticipated future consumables suppliers of IA 2015 clinical participants
Table 8.21. Anticipated future consumables suppliers of IA 2015 clinical participants
8.23. Consumables Costs
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
Figure 8.22. Relative immunoassay costs of IA 2015 clinical participants
8.24. Needs or Innovation Requirements
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
Figure 8.23. Top ten immunoassay needs or innovation requirements of IA 2015 clinical participants
CHAPTER 9. IMMUNOASSAY GROWTH TRENDS (P.146)
9.1. This Chapter
9.2. Recent Growth Trends
Figure 9.1. Top ten recent growth levels in the use of immunoassay, indicated by IA 2015 participants
Table 9.1. Recent growth levels in the use of immunoassay, indicated by IA 2015 participants
9.3. Future Growth Trends
Figure 9.2. Top ten growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
Table 9.2. Growth levels in the use of immunoassay over the next three years, anticipated by IA 2015 participants
CHAPTER 10. DISEASE BIOMARKERS (P.150)
10.1. This Chapter
10.2. Biomarker Disease Areas
Figure 10.1. Top disease areas to which IA 2015 participant's immunoassay biomarker studies relate
Table 10.1. Disease areas to which IA 2015 participant's immunoassay biomarker studies relate
10.3. Purposes of immunoassay Biomarker Studies
Figure 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
Table 10.2. Purposes or reasons for carrying out immunoassay disease biomarker studies, indicated by IA 2015 participants
10.4. Clinical Utility of immunoassay Disease Biomarkers
Figure 10.3. Top clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
Table 10.3. Clinical utilities of immunoassay biomarker studies, indicated by IA 2015 participants
CHAPTER 11. COSTS (P.155)
11.1. This Chapter
11.2. Costs
Figure 11.1. Top per-sample costs levels using immunoassay, indicated by IA 2015 participants
Table 11.1. Per-sample costs levels using immunoassay, indicated by IA 2015 participants
CHAPTER 12. SAMPLE THROUGHPUT (P.158)
12.1. This Chapter
12.2. Sample Throughput
Figure 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
Table 12.1. Monthly sample throughput using immunoassay, indicated by IA 2015 participants
CHAPTER 13. DISCUSSION (P.161)
13.1. Discussion
